On March 16, 2010, an anticipated 1,000 advocates will band together for lupus in person and virtually by phone, email, and through social media networks, to share their personal stories with Members of Congress during the Lupus Foundation of America’s, (LFA) Twelfth Annual Advocacy Day. Advocates’ personal stories will demonstrate how the gaps in lupus research and understanding have a profound effect on the estimated 1.5 million people in the United States who are living with the disease. It has been more than 50 years since the U.S…

Researchers have identified a new disease mechanism and therapeutic approach for a type of advanced kidney disease that is a common cause of complications in patients with lupus.

The Lupus Foundation of America, Inc. (LFA) is seeking applications for its 2010 Gina M. Finzi Memorial Student Summer Fellowship Program. The purpose of these awards is to foster an interest among young investigators in lupus research under the supervision of an established in investigator.

If you ever thought the stress of seeing your extended family over the holidays was slowly killing you — bad news: a new study shows that you might be right. Here’s the good news: results from the same study might lead to entirely new treatments that help keep autoimmune diseases like lupus, arthritis, and eczema under control.

Identical twins look the same and are nearly genetically identical, but environmental factors and the resulting cellular changes could cause disease in one sibling and not the other. In a study published online in Genome Research (www.genome.org), scientists have studied twins discordant for the autoimmune disease lupus, mapping DNA modifications across the genome and shedding light on epigenetic changes that may play a role in the disease…

If you ever thought the stress of seeing your extended family over the holidays was slowly killing you - bad news: a new research report in the December 2009 print issue of the Journal of Leukocyte Biology shows that you might be right. Here’s the good news: results from the same study might lead to entirely new treatments that help keep autoimmune diseases like lupus, arthritis, and eczema under control…

ImmuPharma PLC announced the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.

Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA™ (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology.

Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA™ (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology.

Individuals with a history of lupus who receive a kidney transplant rarely develop the serious inflammatory condition lupus nephritis in their new organ, according to a paper being presented at the American Society of Nephrology’s 42nd Annual Meeting and Scientific Exposition in San Diego, CA.